Lauren Veltri, MD
Hematology & Oncology · Morgantown, WVNPI 1124344601
Payments from drug & device makers
What this record shows
This record is dominated by education: $56 of the $77 with a category attached, or 73.2%. 3 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 42.6% of the total. That places this record below the midpoint for hematology & oncology clinicians in WV, where the typical reported total is $1,186.
Across 3 payments — averaging $25.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$33
- Kyowa Kirin, Inc.$24
- Merck$21
Across 117 payments — averaging $11,861 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$1.1M
- AbbVie$88K
- Genentech, Inc.$83K
- Bristol Myers Squibb$46K
- Acerta Pharma LLC$31K
- Janssen Research & Development, LLC$20K
- plus $68K from 6 others
What the payments were for
- Food & beverage$2127%
- Education$5673%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Merck | 1 | $21 |
How this compares
$77 in reported general payments places this provider in the 10th percentile of 72 hematology & oncology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 109 | $1,593,459 |
| BrukinsaZanubrutinib | 43 | $616,268 |
| JakafiRuxolitinib Phosphate | 37 | $599,665 |
| PomalystPomalidomide | 20 | $456,573 |
| SprycelDasatinib | 26 | $402,681 |
| ImbruvicaIbrutinib | 23 | $366,834 |
| PromactaEltrombopag Olamine | 13 | $364,876 |
| NexavarSorafenib Tosylate | 12 | $272,971 |
| CalquenceAcalabrutinib Maleate | 19 | $271,427 |
| VenclextaVenetoclax | 15 | $170,425 |
| SorafenibSorafenib Tosylate | 14 | $76,152 |
| RydaptMidostaurin | 13 | $61,506 |
| Posaconazole | 22 | $32,087 |
| Atovaquone | 22 | $16,200 |
| EliquisApixaban | 16 | $10,427 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Morgantown
- Abraham KanateMorgantown$169K
- Ashkan EmadiMorgantown$88K
- Konstantinos SdrimasMorgantown$81K
- Ihtishaam QaziMorgantown$18K
- Sonikpreet AulakhMorgantown$17K
- Salah Ud Din SafiMorgantown$5K
- Michael CraigMorgantown$5K
- Joanna KolodneyMorgantown$3K
- Amir KamranMorgantown$2K
- Sobha KurianMorgantown$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.